 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | SPL-108 / Splash Pharma
Journal: Normative Voice Range Profile of the Young Female Voice. (Pubmed Central) - Jul 14, 2023
A normative dataset usable for optimization of future voice assessments has been established. It may especially benefit evaluation and treatment planning for younger females suffering from vocal fold nodules.
- || SPL-108 / Splash Pharma
P1 data, Journal, Combination therapy: Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer. (Pubmed Central) - Jun 25, 2022
P1
The combination of SPL-108 with weekly paclitaxel was safe and well tolerated. Encouraging antitumor activity was observed, with 72% of patients deriving a clinical benefit.
- SPL-108 / Splash Pharma
PARP and ABCB1 (MDR1) inhibitor treatment of ovarian cancer cell lines and PDX models demonstrate no synergistic effect (TBD) - Jan 26, 2022 - Abstract #SGO2022SGO_424;
Encouraging antitumor activity was observed, with 72% of patients deriving a clinical benefit. Learning Objective: Discuss the relationship between novel therapeutic agent SPL-108 in the context of parp inhibitor resistance
- SPL-108 / Splash Pharma
[VIRTUAL] SPL-108 mediates metastasis and chemoresistance in high-grade serous tubo-ovarian carcinoma () - Jan 29, 2021 - Abstract #SGO2021SGO_239;
- SPL-108 / Splash Pharma, paclitaxel / Generic mfg.
[VIRTUAL] Open label phase I trial using SPL-108 in combination with weekly paclitaxel final report with molecular correlates. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4557;
The promising clinical activity on drug resistant ovarian tumors warrants further investigation. Resistance to SPL-108 are characterized by lack of function of TP53, mostly early truncations.
- | SPL-108 / Splash Pharma
Trial completion date, Combination therapy, Metastases: Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer (clinicaltrials.gov) - Mar 18, 2020
P1, N=14, Active, not recruiting, Sponsor: Splash Pharmaceuticals, Inc.
Resistance to SPL-108 are characterized by lack of function of TP53, mostly early truncations. Trial completion date: Feb 2020 --> Jun 2020
- | SPL-108 / Splash Pharma
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer (clinicaltrials.gov) - Sep 30, 2019
P1, N=14, Active, not recruiting, Sponsor: Splash Pharmaceuticals, Inc.
Trial completion date: Feb 2020 --> Jun 2020 Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Feb 2020 | Trial primary completion date: Nov 2018 --> Dec 2019
- | SPL-108 / Splash Pharma
New P1 trial, Combination therapy, Metastases: Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer (clinicaltrials.gov) - Mar 12, 2017
P1, N=18, Not yet recruiting, Sponsor: Splash Pharmaceuticals, Inc.